Distribution of influenza virus types by age using case-based global surveillance data from twenty-nine countries, 1999-2014 by Caini, Saverio et al.
RESEARCH ARTICLE Open Access
Distribution of influenza virus types by age
using case-based global surveillance data
from twenty-nine countries, 1999-2014
Saverio Caini1*, Peter Spreeuwenberg1, Gabriela F. Kusznierz2, Juan Manuel Rudi2, Rhonda Owen3,
Kate Pennington3, Sonam Wangchuk4, Sonam Gyeltshen4, Walquiria Aparecida Ferreira de Almeida5,
Cláudio Maierovitch Pessanha Henriques5, Richard Njouom6, Marie-Astrid Vernet6, Rodrigo A. Fasce7,
Winston Andrade7, Hongjie Yu8, Luzhao Feng8, Juan Yang8, Zhibin Peng8, Jenny Lara9, Alfredo Bruno10,
Doménica de Mora10, Celina de Lozano11, Maria Zambon12, Richard Pebody13, Leticia Castillo14, Alexey W. Clara15,
Maria Luisa Matute16, Herman Kosasih17, Nurhayati17, Simona Puzelli18, Caterina Rizzo19, Herve A. Kadjo20,
Coulibaly Daouda21, Lyazzat Kiyanbekova22, Akerke Ospanova23, Joshua A. Mott24,25, Gideon O. Emukule24,
Jean-Michel Heraud26, Norosoa Harline Razanajatovo26, Amal Barakat27, Fatima el Falaki27, Sue Q. Huang28,
Liza Lopez28, Angel Balmaseda29, Brechla Moreno30, Ana Paula Rodrigues31, Raquel Guiomar32, Li Wei Ang33,
Vernon Jian Ming Lee34, Marietjie Venter35,36, Cheryl Cohen37,38, Selim Badur39, Meral A. Ciblak39, Alla Mironenko40,
Olha Holubka40, Joseph Bresee41, Lynnette Brammer41, Phuong Vu Mai Hoang42, Mai Thi Quynh Le42,
Douglas Fleming43, Clotilde El-Guerche Séblain44, François Schellevis1,45, John Paget1 and Global Influenza B Study
group
Abstract
Background: Influenza disease burden varies by age and this has important public health implications. We
compared the proportional distribution of different influenza virus types within age strata using surveillance data
from twenty-nine countries during 1999-2014 (N=358,796 influenza cases).
Methods: For each virus, we calculated a Relative Illness Ratio (defined as the ratio of the percentage of cases in an
age group to the percentage of the country population in the same age group) for young children (0-4 years),
older children (5-17 years), young adults (18-39 years), older adults (40-64 years), and the elderly (65+ years). We
used random-effects meta-analysis models to obtain summary relative illness ratios (sRIRs), and conducted meta-
regression and sub-group analyses to explore causes of between-estimates heterogeneity.
Results: The influenza virus with highest sRIR was A(H1N1) for young children, B for older children, A(H1N1)
pdm2009 for adults, and (A(H3N2) for the elderly. As expected, considering the diverse nature of the national
surveillance datasets included in our analysis, between-estimates heterogeneity was high (I2>90%) for most sRIRs.
The variations of countries’ geographic, demographic and economic characteristics and the proportion of
outpatients among reported influenza cases explained only part of the heterogeneity, suggesting that multiple
factors were at play.
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Conclusions: These results highlight the importance of presenting burden of disease estimates by age group and
virus (sub)type.
Keywords: Influenza, Age distribution, Influenza A virus, H3N2 subtype, Influenza A virus, H1N1 subtype, Influenza B
virus, Meta-analysis
Background
Several studies have shown that the disease burden and
costs of influenza vary considerably by age group [1, 2].
Among adults, influenza is usually a self-limiting disease
and the social costs are mainly due to loss of productivity
and workdays and to absenteeism due to the need to care
for family members [3]. At the extremes of age there is a
much higher risk of complications, hospitalization and
influenza-associated death [4, 5], especially among older
people with underlying conditions such as chronic heart
disease or diabetes [6]. In these age groups, the costs for
society are mainly related to healthcare.
The influenza burden of disease varies substantially
across seasons [1]. This depends on the circulating virus
strains and, where vaccination campaigns are imple-
mented, on the vaccine uptake rate as well. Overall, the
disease burden of influenza is thought to be higher in
seasons dominated by A(H3N2) or A(H1N1)pdm2009
influenza viruses, and lower in seasons where
pre-pandemic A(H1N1) or influenza B account for the
majority of cases [7, 8].
The dependency of the disease burden in a given sea-
son on circulating influenza virus (sub)types may be due
to two factors that are complementary to each other. On
one hand, influenza viruses may differ between one an-
other in terms of their ability to induce a severe or com-
plicated clinical illness, for instance by favouring
bacterial co-infections, worsening of underlying condi-
tions, or other life-threatening events. This hypothesis
has been questioned by studies showing that there were
only negligible differences in the age-adjusted clinical
presentation and severity of the illness caused by differ-
ent influenza virus types and subtypes [9–12]. On the
other hand, the influenza viruses may differ between one
another in how frequently they affect certain age groups.
For instance, school-age children are more affected dur-
ing influenza seasons dominated by pre-pandemic
A(H1N1) and B virus strains than during A(H3N2)-do-
minated season [13].
The age distribution of influenza cases is likely to be
affected by several other factors beyond the mix of circu-
lating virus (sub)types , which may vary considerably in
space and time. These include the country’s demo-
graphic and geographic characteristics, the implementa-
tion of vaccination campaigns against influenza, and
past epidemics that affect the immunity of the different
population age groups. In addition, how the influenza
surveillance system is structured, the general perception
of the severity of the season (for example, during the
2009 pandemic), and health care seeking behaviour may
determine how many and what influenza cases are seen
in each season and country. The availability of a global
database with age-specific data enables an analysis of
patterns across different settings and facilitates stronger
conclusions, provided there is careful examination of
how the age distribution of influenza cases fluctuated
across countries and seasons, and investigating the influ-
ence of potential confounding factors.
Here, we compared the proportional distribution of
different influenza virus (sub)types within age strata
using the database of the Global Influenza B Study
(GIBS).
Methods
Sources of data and definitions
The GIBS was launched in 2012 with the aim of in-
creasing the scientific evidence needed to optimize
the influenza prevention policies worldwide [14]. Ex-
perts from over fifty countries from all continents
were invited to provide data on the weekly number of
influenza cases reported to their national influenza
surveillance system during recent years (ideally, from
2000 onwards) (N=948,646). Importantly, and in con-
trast to other global surveillance databases (e.g. Flu-
Net) [15], the GIBS database also includes the age
(exact age or age group) of each reported influenza
case. From large countries we asked to provide data
stratified at a sub-national level, if available (for brev-
ity, we will use the term “country” to refer to a whole
country or to a sub-national region of it hereinafter).
Experts from participating countries were also re-
quested to describe the main characteristics of their
influenza surveillance system.
Country-specific geographic, demographic and so-
cioeconomic information necessary for the analyses
was derived from the US Central Intelligence Agency
World Factbook website [16]. This includes informa-
tion on the population age structure, the ageing index
(defined as the number of people aged 65 years or
older per hundred people aged 14 years or younger),
the latitude of the population centroid (when avail-
able) or of the largest city, and the per capita gross
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domestic product (GDP). In terms of latitude, a coun-
try was considered as being situated in the Northern
or Southern hemisphere or in the inter-tropical belt
based on the latitude of its centroid/largest city.
Statistical analysis
For brevity, we will describe the outcome variable by
referring to “influenza”, and the method was applied
to A(H1N1), A(H1N1)pdm2009, A(H3N2), and influ-
enza B viruses separately; influenza cases that could
not be classified in an unambiguous way to any of
the above (for instance, those classified as “unsub-
typed influenza A”) were not included in the analysis.
The statistic used to describe the age distribution of
influenza cases in each season and country is the
Relative Illness Ratio (RIR) [17], which is defined as
the ratio of the percentage of influenza cases in a
given age group to the percentage of the general
population belonging to the same age group. We con-
sidered the following age groups: 0-4 years (referred
to as “young children” hereinafter), 5-17 years (“older
children”), 18-39 years (“young adults”), 40-64 years
(“older adults”), and 65+ years (“elderly”). A RIR was
calculated for each of these five age groups in each
influenza season in which there were at least 100 re-
ported influenza cases overall; 95% confidence inter-
vals (95% CI) were calculated by using an exact
method based on the Poisson distribution [18].
When calculating a RIR, the null hypothesis is that the
chance of being infected with influenza is the same for
all people irrespective of their age, implying an age dis-
tribution of influenza cases perfectly equal to that of the
general population and the RIR equal to 1 in each age
group. Therefore, a RIR equal to 3 for influenza B in the
age group 5-17 years would mean that, in that season,
the proportion of influenza B cases aged 5-17 years was
three times the proportion of the general population of
the same age group, i.e. three times higher than expected
if all age groups would be equally affected by influenza.
All RIRs obtained in the different seasons and coun-
tries were pooled into a summary Relative Illness Ratio
(sRIR) (separately for each age group) through
random-effects meta-analysis models by using the
method by DerSimonian and Laird [19]. Comparisons
between pairs of sRIRs were conducted, within each age
group, through meta-regression models that included an
interaction term for the virus (sub)type.
We assessed the between-estimates heterogeneity by
using the I2 statistics, which can be interpreted as the
percentage of total variation that is attributable to
heterogeneity [20]. We expected a high degree of het-
erogeneity (this was an a priori consideration), as
many factors combine to determine the age distribu-
tion of influenza surveillance cases in any given
country and season. In order to assess this point in
detail, we fitted meta-regression models and per-
formed sub-group analysis to explore possible corre-
lates of between-estimates heterogeneity, using the
proportion of outpatients among reported influenza
cases, the percentage of all influenza cases caused by
each influenza virus (sub)type in the same or in the
previous season, and the country’s latitude, ageing
index and per capita GDP.
All analyses were conducted using Stata version 14
(Stata Corp, College Station, TX). We used the metan
command (with the option random) to pool the country-
and season-specific RIR into a sRIR, obtain forest plots,
and calculate the I2 statistics [21]. The study of
between-estimates heterogeneity was conducted by using
the metareg command [21]. Maps were prepared using
freely available software (http://mapchart.net/).
All statistical tests were two-sided, and p-values of less
than 0.05 were considered as statistically significant.
Comparing the age of influenza cases
The interpretation of sRIRs requires caution. The age
distribution of patients infected with any given influ-
enza virus in each season and country is affected by a
number of socio-economic factors, including health-
care seeking behaviour, influenza testing by age, and
the way primary and hospital care are organized and
delivered. The chance of seeking medical attention
(and consequently being seen by an influenza surveil-
lance system) once a person is infected is very prob-
ably not the same in all age groups across all
participating countries. For instance, children and the
elderly might be over-represented in both general
practitioners- and (especially) hospital-based surveil-
lance systems, as they seek medical attention more
frequently when they are sick compared to adults.
Therefore, we believe a “same virus, different age
groups” approach (i.e. a comparison of sRIRs between
people of different age groups infected with the same
influenza virus) is not correct. In other words, it is
not possible to answer the question “Are young chil-
dren more or less affected than adults (or another age
group) by influenza and by how much?” by inferring
from the age distribution of cases reported to the in-
fluenza surveillance system.
Instead, there is no major obstacle in ranking the
sRIRs for people of the same age group who are in-
fected with different influenza virus (sub)types
(“different viruses, same age group” approach). As
mentioned, there are only minor differences in the
clinical presentation of influenza illness produced by
the different virus types within each age group
[9–12]. This implies that the likelihood of seeking
medical attention is likely to be similar for people of
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any given age group in the same country who are in-
fected with different influenza viruses. It is therefore
possible to answer the question “Are young children
more or less affected by influenza B compared to in-
fluenza A(H3N2)?”.
Results
The GIBS database that was used for the analysis in-
cluded 358,768 influenza cases reported between 1999
and 2014 in twenty-nine countries (Table 1 and Fig. 1),
of which four were in the Southern hemisphere, fifteen in
Table 1 Selected features of countries included in the study of age distribution of influenza cases. The Global Influenza B Study,
1999-2014
Country Latitude (a) Population
(million)
Ageing
index (b)
GDP per
capita (USD)
% of
outpatients (c)
No. influenza cases (seasons) included in the analysis:
A(H1N1) A(H1N1)pdm2009 A(H3N2) B
Southern hemisphere
New Zealand 41.8 S 4.5 0.72 30,400 30% 2,274 (5) 3,763 (3) 4,840 (8) 2,763 (7)
Chile 35.8 S 16.6 0.48 19,100 5% 403 (1) 5,399 (3) 3,540 (3) 897 (2)
South Africa 29.0 S 53.0 0.22 11,500 0% - (0) 432 (3) 421 (3) 527 (3)
Australia 25.8 S 23.4 0.84 43,000 50% 3,614 (6) 50,096 (4) 13,286 (9) 28,673 (12)
Inter-tropical belt
Madagascar 19.4 S 21.3 0.08 1,000 100% 109 (1) 1,101 (2) 579 (4) 1,004 (4)
Brazil (d) 10.8 S 201.0 0.32 12,100 NA - (0) - (0) - (0) 665 (4)
Ecuador 2.0 S 15.4 0.24 10,600 0% - (0) 673 (2) 713 (3) 185 (1)
Indonesia 1.7 S 237.4 0.25 5,200 95% 720 (2) - (0) 1,397 (4) 1,281 (4)
Kenya 0.4 S 44.4 0.07 1,800 40% 365 (2) 1,285 (3) 1,183 (5) 1,454 (5)
Singapore 1.2 N 5.4 0.63 62,400 100% - (0) 2,634 (3) 1,436 (3) 1,483 (3)
Cameroon 5.7 N 22.5 0.07 2,400 90% - (0) - (0) 259 (2) 102 (1)
Ivory Coast 7.6 N 23.2 0.09 1,800 83% - (0) 344 (2) 171 (1) 446 (2)
Panama 8.6 N 3.7 0.28 16,500 39% - (0) 744 (1) 321 (2) 154 (1)
Costa Rica 10.0 N 4.6 0.30 12,900 27% - (0) 4,069 (2) 1,026 (4) 387 (2)
Nicaragua 12.9 N 6.1 0.16 4,500 43% - (0) 3,113 (3) 1,089 (4) 699 (3)
El Salvador 13.8 N 6.1 0.25 7,500 22% - (0) 858 (2) 317 (2) 437 (3)
Honduras 14.8 N 8.2 0.11 4,800 56% - (0) 656 (2) 277 (2) - (0)
Guatemala 15.7 N 15.4 0.12 5,300 72% 263 (1) 1,681 (3) 169 (1) 316 (2)
Viet Nam 16.7 N 89.7 0.23 4,000 40% 1,218 (2) 1,368 (3) 2,781 (6) 2,982 (8)
Northern hemisphere
Bhutan 27.4 N 0.7 0.22 2,600 97% - (0) 510 (2) 130 (1) 101 (1)
China South (e) 31.1 N 969.4 0.56 9,800 100% 5,530 (5) 40,754 (2) 30,299 (7) 35,910 (8)
Morocco 32.0 N 33.2 0.24 5,500 70% - (0) 2,076 (2) 354 (2) - (0)
Turkey 39.0 N 76.7 0.26 15,300 100% 1,298 (2) - (0) - (0) 289 (1)
Portugal 39.3 N 10.4 1.17 22,900 97% - (0) 648 (3) 2,085 (8) 733 (4)
China North (e) 39.5 N 370.9 0.56 9,800 100% 3,900 (5) 22,951 (3) 13,054 (7) 19,956 (7)
Italy 42.9 N 59.9 1.52 29,600 60% - (0) 3,880 (2) 1,900 (2) 493 (1)
Kazakhstan 48.0 N 17.9 0.28 14,100 5% - (0) 108 (1) 421 (3) 163 (1)
Ukraine 49.1 N 44.6 1.14 7,400 NA - (0) 104 (1) - (0) - (0)
England (f) 52.3 N 53.0 0.91 37,300 57% 179 (1) 2,438 (3) 1,743 (6) 1,319 (3)
19,873 (33) 151,685 (60) 83,791 (102) 103,419 (93)
NA: not available
(a) Latitude of centroid (when available) or largest city
(b)Defined as the number of people aged 65 years or older per hundred people aged 14 years or younger
(c)Proportion of outpatients among reported influenza cases
(d)Information on subtype of influenza A cases was not available for Brazil
(e)Ageing index and GDP per capita of China (whole country)
(f)Ageing index and GDP per capita of United Kingdom
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the inter-tropical belt, and ten in the Northern hemi-
sphere. In detail, there were 19,873 influenza A(H1N1)
cases from 33 seasons in twelve countries; 151,685 influ-
enza A(H1N1)pdm2009 cases from 60 seasons in
twenty-five countries; 83,791 influenza A(H3N2) cases
from 102 seasons in twenty-six countries; and 103,419 in-
fluenza B cases from 93 seasons in twenty-six countries.
The number of influenza cases (by influenza virus) that
was available for the analysis in each country and season
(i.e. with age information available and at least 100 cases
reported in the season, and after excluding non-subtyped
influenza A cases) is reported in the Additional file 1.
The overall age distribution of influenza cases was as fol-
lows: 19% in young children, 33% in older children, 30% in
young adults, 14% in older adults and 4% in the elderly.
The sRIRs for each influenza virus (sub)type by age group
are reported in Table 2 (we provide a sample of the corre-
sponding forest plots, namely those for A(H1N1), in the
Additional file 2 ). The sRIR for young children was highest
for influenza A(H1N1) (3.57, 95%CI 3.00-4.14) and lowest
for influenza A(H1N1)pdm2009 (2.93, 95%CI 2.68-3.19);
for older children, the sRIR was highest for influenza B
(1.69, 95%CI 1.53-1.85) and lowest for influenza A(H3N2)
(1.04, 95%CI 0.93-1.14); for both young and older adults, it
was highest for influenza A(H1N1)pdm2009 (0.94, 95%CI
0.87-1.01 and 0.62, 95%CI 0.55-0.69, respectively) and low-
est for influenza B (0.65, 95%CI 0.59-0.71 and 0.41, 95%CI
0.37-0.45, respectively); for the elderly it was highest for
influenza A(H3N2) (0.74, 95%CI 0.66-0.83) and lowest for
influenza A(H1N1) (0.16, 95%CI 0.12-0.20). The
between-estimates heterogeneity was large, as it exceeded
95% for all of the sRIRs among young children, older chil-
dren and young adults, and was above 90% for all of the
sRIRs calculated among older adults and the elderly (with
the only exception of the elderly infected with influenza
A(H1N1), where it was 73.9%) (Table 2). Because of the
large between-estimates heterogeneity, the summary esti-
mates should not be interpreted in a precise manner, and
the reported 95% confidence intervals most likely under-
estimate the real uncertainty in the data and should be con-
sidered with caution.
Latitude, ageing index, GDP per capita and the proportion
of outpatients among reported influenza cases were signifi-
cantly (p<0.05) correlated with sRIRs for most influenza virus
(sub)types and age groups (Table 3). Countries’ geographic,
demographic, economic and epidemiological characteristics
explained a smaller part of between-estimates heterogeneity
for A(H1N1) compared to the other influenza virus
(sub)types.
Inspection of stratified sRIRs (available in the
Additional file 3) revealed some additional patterns.
Pre-pandemic A(H1N1) was the most frequent virus
subtype in the 0-4 years age group only in the North-
ern hemisphere, while A(H3N2) prevailed in the
inter-tropical belt and the Southern hemisphere. The
proportion of outpatients among reported cases con-
sistently affected the sRIRs among young children and
the elderly (sRIR was highest when the proportion of
outpatients accounted for less than 40% in the data),
and the country’s demographic structure consistently
Fig. 1 Countries included in the analysis on the age distribution of influenza cases by virus type and subtype. The Global Influenza B Study,
1999-2014. The map was prepared using freely available software (http://mapchart.net/)
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affected the sRIRs among older children and young
adults (sRIR was highest when ageing index >0.50).
Importantly, the stratified analysis indicated that the
results for countries with 70% or more reported influ-
enza cases from outpatients mirror those for the
whole database, with pre-pandemic A(H1N1), B,
pandemic A(H1N1)2009 and A(H3N2) being the
most frequently detected virus strain among young
children, older children, young adults and the eld-
erly, respectively. For the other variables, the pat-
tern of sRIRs across values was inconsistent across
influenza virus (sub)types, making it difficult to
identify a clear pattern. The between-estimates het-
erogeneity remained very high (>90%) for most
stratified sRIRs, irrespective of the influenza virus
(sub)type and age group.
Discussion
We compared the age distribution of influenza cases
across different influenza viruses relative to that of the
general population using the GIBS database, which en-
compasses case-based influenza data from twenty-nine
countries during 1999-2014. We found that each influ-
enza virus had a relatively higher frequency in a certain
age group: influenza A(H1N1) appeared to be relatively
more frequent among young children, B among older
children, A(H1N1)pdm2009 among young and older
adults, and A(H3N2) among the elderly. These results
were confirmed in the analysis limited to countries with
most reported influenza cases coming from the out-
patient setting. In addition, the RIR was highest for
young children and lowest for older adults and the eld-
erly whatever the virus strain examined, suggesting that
the young children are the age group most affected by
influenza in relation to their size in the country’s popula-
tion. Importantly, however, because of the possible
over-representation of children and elderly people in our
study sample and of the large (but expected) heterogen-
eity, we have restrained ourselves from, and cautioned
against, interpreting the point estimates in a precise way.
In addition, it is very likely that the confidence intervals
underestimate the real uncertainty in the data. As a re-
sult, we have limited ourselves to ranking the sRIRs for
the different influenza virus (sub)types within any given
age group (i.e. following a “different viruses, same age
group” approach, as explained), and to drawing more
cautious conclusions regarding the results.
Many factors affect the probability of being infected
with influenza and of being captured by a national influ-
enza surveillance system in each age group. The factors
include epidemiological characteristics like the number
of effective contacts among susceptible people, the
country’s population density and mobility [22, 23], the
typical family composition and the average number of
people living in a household [24, 25], and the pattern of
contacts between people of different age groups [26–28].
Other important factors include influenza vaccine
uptake and how national surveillance systems are
structured (e.g. community and/or hospital based).
These many factors, and the virus strains that are
circulating, interact in a complex way to produce a
net effect that defines the cases that are captured by
the national surveillance systems. This situation may
explain the large degree of heterogeneity in our data,
which persisted also when conducting the stratified
analysis. Because of this, we opted to (i) analyse our
data by age group (to control for some of the factors
listed above, e.g. the different probability by age of
being tested and therefore being reported to the na-
tional surveillance system), (ii) present patterns for
each influenza virus (sub)type, and (iii) draw
Table 2 Summary Relative Illness Ratio (sRIR), lower and upper
95% confidence intervals (CI), and between-estimates
heterogeneity (as measured by the I2 statistics) for A(H1N1),
A(H1N1)pdm2009, A(H3N2) and B influenza virus within each
age group. The Global Influenza B Study, 1999-2014
Influenza virus sRIR lower CI (a) upper CI (a) I2
Young children (0-4 years)
A(H1N1) 3.57 3.00 4.14 97.5%
A(H1N1)pdm2009 2.28 2.10 2.46 97.8%
A(H3N2) 3.30 2.95 3.64 98.2%
B 2.93 2.68 3.19 97.5%
Older children (5-17 years)
A(H1N1) 1.36 1.19 1.54 95.2%
A(H1N1)pdm2009 1.23 1.02 1.45 99.5%
A(H3N2) 1.04 0.93 1.14 97.2%
B 1.69 1.53 1.85 98.4%
Young adults (18-39 years)
A(H1N1) 0.84 0.72 0.96 97.1%
A(H1N1)pdm2009 0.94 0.87 1.01 97.5%
A(H3N2) 0.73 0.68 0.78 96.0%
B 0.65 0.59 0.71 98.1%
Older adults (40-64 years)
A(H1N1) 0.49 0.41 0.57 95.2%
A(H1N1)pdm2009 0.62 0.55 0.69 98.7%
A(H3N2) 0.59 0.55 0.63 93.5%
B 0.41 0.37 0.45 96.6%
Elderly (65+ years)
A(H1N1) 0.16 0.12 0.20 73.9%
A(H1N1)pdm2009 0.27 0.24 0.31 94.7%
A(H3N2) 0.74 0.66 0.83 95.2%
B 0.38 0.33 0.43 92.4%
(a)Because of the between-estimates heterogeneity being above 50%, the
reported 95% CI very likely underestimate the real uncertainty in the data, and
should be considered with caution.
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cautious conclusions and avoid giving precise effect
estimates.
The main strength of our study is the wealth of data
included in the GIBS database and the large diversity of
countries in terms of their geographical, socio-economic
and epidemiological characteristics. This allowed us to
investigate simultaneously the effect of several factors on
the age distribution of influenza cases relative to that of
the general population, which would not have been pos-
sible by using data from a single country (or a few coun-
tries that are very similar to one another) or for a
limited number of seasons. The large heterogeneity in
the data prevented us from quantifying the effect of the
virus (sub)type on the age distribution of influenza cases
in a precise way, and therefore, to answer in a definitive
way our study question. However, the adoption of a
meta-analytical approach allowed us to describe the
between-estimates heterogeneity both analytically and
graphically, and was especially useful in exploring the
many factors that contribute to determine the age distri-
bution of influenza cases in any given country and
season.
The main limitation of the paper is its reliance on data
that was not purposely collected to answer the main
study question. Passive influenza surveillance systems
only allow inferences regarding medically-attended influ-
enza virus infections, and are inherently unable to cap-
ture infected people who do not seek medical care.
While this does not represent a limitation for the main
goals of surveillance (i.e. early warning of epidemics),
the data collected within a passive surveillance system
may be sub-optimal for purely research purposes. In par-
ticular, influenza surveillance systems differ across coun-
tries included in GIBS in terms of the proportion of
outpatients compared to all reported influenza cases,
which may represent an important source of bias for the
present analysis [14]. Reassuringly, our results were con-
firmed when limiting the analysis to countries in which
over 70% of influenza cases were outpatients (i.e. origi-
nated from a community-based surveillance system).
However, meta-regression and subgroup analysis are not
as powerful as an analysis which takes advantage of
individual-level data, which is warranted in order to con-
firm or refute our findings. In general, the “same virus,
different age groups” interpretation of results is not pos-
sible using passive surveillance data. To allow for a more
reliable comparison of influenza burden between age
groups using surveillance data, each country would need
to adopt a sampling protocol for virological testing that
allows the probability to sample a (suspected) influenza
case in each age group to be known in advance. Despite
being quite expensive, active surveillance based on par-
ticipatory cohorts would allow a better understanding of
influenza epidemiology by providing the opportunity to
estimate key epidemiological parameters, including the
age distribution of cases and the age-specific attack rate,
frequency of complications and mortality [29]. A further
limitation of our study is the lack of age data for coun-
tries in North America, in particular for United States;
in addition, some countries contributed data for only a
limited number of seasons. The proportion of influenza
patients being typed and subtyped may depend on the
patient’s age: this may have introduced a bias whose
magnitude, however, should have been attenuated by our
decision to analyse the data separately within each age
group. Finally, we could not run separate analyses by
influenza B virus lineage (Yamagata vs. Victoria), as this
information was available in only a small percentage of
influenza B cases.
Conclusions
Global surveillance data for the start of the 21st century
suggest that the relative proportion of influenza cases
caused by each influenza virus (sub)type may differ by
age group. Our results suggest that the mix of circulat-
ing influenza viruses is one among several factors that
are at play in determining the differing age distribution
of influenza surveillance cases, and highlight the import-
ance of presenting disease burden estimates by age
group and virus (sub)type.
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